### **DEPARTMENT OF JUSTICE**

Drug Enforcement Administration [Docket No. DEA-392]

Bulk Manufacturer of Controlled Substances Application: Chattem Chemicals, Inc.

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before December 21, 2015.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODXL, 8701 Morrissette Drive, Springfield, Virginia 22152. Request for hearings should be sent to: Drug Enforcement Administration, Attention: Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated her authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Deputy Assistant Administrator of the DEA Office of Diversion Control ("Deputy Assistant Administrator") pursuant to section 7 of 28 CFR part 0, appendix to subpart R. In accordance with 21 CFR 1301.33(a), this is notice that on July 22, 2015. Chattem Chemicals, Inc., 3801 St Elmo Avenue, Chattanooga, Tennessee 37409 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

| Controlled substance        |                |      | Schedule |
|-----------------------------|----------------|------|----------|
| Gamma (2010).               | Hydroxybutyric | Acid | I        |
| 4-Methoxyamphetamine (7411) |                |      | 1        |
| Dihydromorphine (9145)      |                |      | 1        |
| Amphetam                    | II             |      |          |
| Methamphetamine (1105)      |                |      | II       |
| Lisdexamfetamine (1205)     |                |      | II       |
| Methylphenidate (1724)      |                |      | П        |
| Pentobarbital (2270)        |                |      | П        |
| Codeine (9050)              |                |      | П        |
| Dihydrocodeine (9120)       |                |      | lii      |
| Oxycodone (9143)            |                |      | П        |

| Controlled substance | Schedule |
|----------------------|----------|
| Hydromorphone (9150) |          |
| , , ,                |          |

The company plans to manufacture the listed controlled substances in bulk for distribution and sale to its customers.

Dated: October 13, 2015.

#### Louis J. Milione,

Deputy Assistant Administrator. [FR Doc. 2015–26682 Filed 10–20–15; 8:45 am]

BILLING CODE 4410-09-P

### **DEPARTMENT OF JUSTICE**

Drug Enforcement Administration [Docket No. DEA-392]

Bulk Manufacturer of Controlled Substances Application: Cody Laboratories, Inc.

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic class, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before December 21, 2015.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODXL, 8701 Morrissette Drive, Springfield, Virginia 22152. Request for hearings should be sent to: Drug Enforcement Administration, Attention: Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated her authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with

respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Deputy Assistant Administrator of the DEA Office of Diversion Control ("Deputy Assistant Administrator") pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.33(a), this is notice that on March 17, 2015, Cody Laboratories, Inc., Steve Hartman—Vice President of Compliance, 601 Yellowstone Avenue, Cody, Wyoming applied to be registered as a bulk manufacturer of methadone intermediate (9254), a basic class of controlled substance listed in schedule II

The company plans to manufacture the listed controlled substance as an intermediate in the manufacture of an active pharmaceutical ingredient to sell to its customers.

Dated: October 13, 2015.

#### Louis J. Milione,

Deputy Assistant Administrator.

[FR Doc. 2015-26670 Filed 10-20-15; 8:45 am]

BILLING CODE 4410-09-P

# **DEPARTMENT OF JUSTICE**

# **Drug Enforcement Administration**

[Docket No. DEA-392]

Bulk Manufacturer of Controlled Substances Application: Cambrex Charles City

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before December 21, 2015.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODXL, 8701 Morrissette Drive, Springfield, Virginia 22152. Request for hearings should be sent to: Drug Enforcement Administration, Attention: Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152. Comments and requests for hearings on applications to import raw material are not appropriate. 72 FR 3417 (January 25, 2007).